Form 8-K - Current report:
SEC Accession No. 0001140361-25-023648
Filing Date
2025-06-25
Accepted
2025-06-25 16:22:38
Documents
12
Period of Report
2025-06-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ef20051087_8k.htm   iXBRL 8-K 29796
  Complete submission text file 0001140361-25-023648.txt   156872

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ird-20250625.xsd EX-101.SCH 3859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250625_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250625_pre.xml EX-101.PRE 16041
14 EXTRACTED XBRL INSTANCE DOCUMENT ef20051087_8k_htm.xml XML 4051
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 251073872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)